Lupins Vizag API facility receives EIR from U.S. FDA, Health News, ET HealthWorld


Mumbai: Pharma bigger Lupine Limited (lupine) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and drug Administration (U.S. FDA) after closing inspection for its Vizag (Vishakhapatnam), India facility.

The API plant inspection was conducted by U.S. FDA between January 13, 2020 and January 17, 2020.

Commenting on the receipt of the EIR, Nilesh Gupta, CEO, Lupine said, “We are very pleased to have received the EIR for our Vizag facility. We remain committed to improving compliance and quality standards at the Vizag plant and across all of our manufacturing sites. “

Follow and connect with us at . Facebook. Linkedin





Source link